The Dementia Discovery Fund 2 (DDF-2) has secured £25m from British Patient Capital, bringing its total raise to US$250m. This fund aims to develop first-in-class dementia therapeutics.

British Patient Capital has made a £25m commitment to the Dementia Discovery Fund 2 (DDF-2), which is managed by SV Health Investors. This investment brings the fund to a total of US$250m. DDF-2 will build on previous advances in neurodegenerative diseases and focus on developing new therapies for dementia. The fund aims to address the significant medical challenges posed by dementia through strategic venture finance.